Drug Profile


Alternative Names: CCX 168

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Mario Negri Institute for Pharmacological Research
  • Class Anti-inflammatories; Cyclopentanes; Piperidines; Small molecules
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anti-neutrophil cytoplasmic antibody-associated vasculitis; Haemolytic uraemic syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Phase II Haemolytic uraemic syndrome; IgA nephropathy
  • Phase I Autoimmune disorders

Most Recent Events

  • 09 Jan 2017 ChemoCentryx plans a clinical trial for Complement 3 Glomerulopathy and Haemolytic uremic syndrome
  • 01 Dec 2016 Phase-III clinical trials in Anti-neutrophil cytoplasmic antibody-associated vasculitis (Combination therapy) in USA (PO) (NCT02994927)
  • 01 Dec 2016 ChemoCentryx completes a phase II trial in IgA nephropathy in USA, Belgium and Sweden (PO) (NCT02384317)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top